Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods - BASF Australia Ltd, The Australian Red Cross Blood Service (Toowoomba, Mackay), Australian Pharmaceutical Manufacturers Pty Ltd, Melrose Laboratories Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to provide a regulatory framework for therapeutic goods in Australia, ensuring their safety, quality, and efficacy. This Act aims to address the problem of maintaining high standards in the manufacturing, distribution, and supply of therapeutic goods to protect public health. The Act was enacted by the Parliament of Australia and its overarching policy objective is to safeguard the health and safety of Australians by regulating therapeutic goods effectively. The Act includes provisions for licensing manufacturers, approving the import and export of goods, and setting standards for advertising and labeling. This legislative measure is crucial in maintaining public confidence in the therapeutic goods market and ensuring that only safe and effective products are available to consumers.

Scope and Application

The Therapeutic Goods Act 1989 applies to all entities involved in the manufacture, supply, and regulation of therapeutic goods within Australia. This encompasses a broad range of entities including companies, corporations, and individuals who are engaged in activities such as the manufacturing, importation, and distribution of therapeutic goods. The Act ensures that therapeutic goods available in Australia meet required safety, quality, and efficacy standards. The geographic reach of the Act is national, extending across the Commonwealth of Australia and affecting all states and territories. While the Act generally applies to all therapeutic goods, certain exclusions and exemptions may apply, particularly for goods that fall under specific categories such as those used for research or for personal use. The application and enforcement of the Act may be further extended or restricted through subordinate instruments, such as regulations and guidelines, which provide detailed provisions and procedures for specific aspects of therapeutic goods regulation. This Gazette notice from the Department of Health, specifically focusing on the revocation of manufacturing licenses, highlights the Act’s role in maintaining the integrity and safety of the therapeutic goods market by ensuring that only authorised and compliant entities are permitted to manufacture these goods.

Key Provisions

The Therapeutic Goods Act 1989, in Section 41(1)(d), allows the Secretary to revoke a Licence to Manufacture Therapeutic Goods. This action has been taken in this instance with respect to five entities: BASF Australia Ltd, The Australian Red Cross Blood Service (two separate licences), Australian Pharmaceutical Manufacturers Pty Ltd, and Melrose Laboratories Pty Ltd. Each of these revocations has occurred at the request of the respective manufacturers. The details of each entity, including their licence numbers and addresses, are provided to ensure transparency and clarity in the revocation process. Entities that hold a Licence to Manufacture Therapeutic Goods under the Therapeutic Goods Act 1989 are subject to specific obligations and requirements. These include maintaining high standards of manufacturing quality and adhering to all relevant regulations and guidelines set forth by the Therapeutic Goods Administration. Manufacturers must also ensure that their products are safe, of good quality, and fit for their intended purpose. Failure to meet these obligations can result in the revocation of their licence, as seen in this case. In terms of consequences for breaches of the Therapeutic Goods Act 1989, the Act outlines both civil and criminal penalties. Civil penalties can include fines, with the exact amount determined by the court based on the severity and nature of the breach. Criminal penalties can include imprisonment, with the maximum term varying depending on the offence. For example, under Section 26 of the Act, a person who commits an offence that results in serious harm to a person can be imprisoned for up to 10 years. The revocation of a manufacturing licence itself is also a significant consequence, as it prevents the entity from legally manufacturing therapeutic goods in Australia. The Therapeutic Goods Act 1989 also includes provisions for the publication of information regarding the revocation of manufacturing licences. This is intended to maintain transparency and inform the public about the status of therapeutic goods manufacturers. Section 41(2) of the Act mandates that the Secretary must publish details of any revocation in the Commonwealth Gazette, as has been done in this instance. This ensures that all stakeholders are aware of any changes in the status of therapeutic goods manufacturers, thereby upholding the integrity of the therapeutic goods market in Australia.